| Glaxo to double China R&D staff in few years |
|
SHANGHAI (Reuters) - GlaxoSmithKline, the world's second-largest drugmaker, plans to double its research and development staff in China to 350 people in the next few years, an executive said on Tuesday.
|
More
-
China Hangzhou city plans $730 mln industrial fund
HANGZHOU, China, July 9 (Reuters) - China's Hangzhou city plans to set up a 5 billion yuan ($730 million) fund to invest in industrial projects and a 560 million yuan venture capital fund to suppor...
-
Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior...
Angiotech Pharmaceuticals, Inc. , a global specialty pharmaceutical and medical device company, today announced the commencement of a cash tender offer of the outstanding notes listed below in an amount that will result in an aggregate purchase price of $165 million for all Notes purchased.